Could TriSalus’ pressure-based drug delivery system change how liver tumors are targeted?
TriSalus has a delivery thesis, not just a device story. PREDICTT will test whether PEDD can make Y90 liver tumor therapy more precise.
TriSalus has a delivery thesis, not just a device story. PREDICTT will test whether PEDD can make Y90 liver tumor therapy more precise.
Medtech startups have sensors, but software can slow them down. Sequenex’s MedTech Innovator tie up targets that commercialization gap.
Breast cancer surgery still struggles with missed margins. Cairn Surgical’s trial raises a sharper question for wire localization.
Trividia’s TRUE METRIX correction is no routine label fix. Glucose meter safety now hinges on software, usability, and upgrade execution.
Europe needs standardized glioma PET imaging. Telix TLX101-Px now tests whether regulators and payers are ready for FET-PET access.
Pancreatic cancer needs local precision. Vector Science is betting a catheter patent can move drug delivery closer to the tumor.
Vision testing is getting faster. PerZeption and Alcon now face the harder test: proving AIM+ CSF can reshape research-grade evidence.
China’s export pitch is moving upmarket. Canton Fair Phase 3 puts smart healthcare and adaptive fabrics at the centre of that shift.
Retina drugs are improving, but delivery remains the bottleneck. Everads Therapy is testing whether suprachoroidal access can change that.
Valve durability is becoming a lifetime-care question. Edwards Lifesciences’ 10-year RESILIA data raise the stakes for heart teams.